Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study

Jesse Gitaka¹,²*, Caroline Ogwang¹*, Moses Ngari¹,³, Pauline Akoo¹, Ally Olotu¹, Christine Kerubo¹, Greg Fegan¹,⁴,⁵, Patricia Njuguna¹, Godfrey Nyakaya¹, Tuda Otieno¹, Gabriel Mwambingu¹, Ken Awuondo¹, Brett Lowe¹,⁴, Roma Chilenga⁶, James A. Berkley¹,³,⁴

¹ Clinical Trials Facility, Kenya Medical Research Institute/Wellcome Trust Research Programme, Kilifi, Kenya, 2 Department of Clinical Medicine, School of Health Sciences, Mount Kenya University, Thika, Kenya, 3 The Childhood Acute Illness & Nutrition Network (CHAIN), Nairobi, Kenya, 4 Centre for Tropical Medicine & Global Health, University of Oxford, Oxford, United Kingdom, 5 Swansea Trials Unit, Swansea University Medical School, Swansea University, Swansea, United Kingdom, 6 Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

* These authors contributed equally to this work.

Abstract

Reference intervals for clinical laboratory parameters are important for assessing eligibility, toxicity grading and management of adverse events in clinical trials. Nonetheless, haematological and biochemical parameters used for clinical trials in sub-Saharan Africa are typically derived from industrialized countries, or from WHO references that are not region-specific. We set out to establish community reference values for haematological and biochemical parameters amongst children aged 4 weeks to 17 months in Kilifi, Kenya. We conducted a cross sectional study nested within phase II and III trials of RTS, S malaria vaccine candidate. We analysed 10 haematological and 2 biochemical parameters from 1,070 and 423 community children without illness prior to experimental vaccine administration. Statistical analysis followed Clinical and Laboratory Standards Institute EP28-A3c guidelines. 95% reference ranges and their respective 90% confidence intervals were determined using non-parametric methods. Findings were compared with published ranges from Tanzania, Europe and The United States. We determined the reference ranges within the following age partitions: 4 weeks to <6 months, 6 months to less than <12 months, and 12 months to 17 months for the haematological parameters; and 4 weeks to 17 months for the biochemical parameters. There were no gender differences for all haematological and biochemical parameters in all age groups. Hb, MCV and platelets 95% reference ranges in infants largely overlapped with those from United States or Europe, except for the lower limit for Hb, Hct and platelets (lower); and upper limit for platelets (higher) and haematocrit(lower). Community norms for common haematological and biochemical parameters differ from developed countries. This reaffirms the need in clinical trials for locally derived reference values to detect deviation from what is usual in typical children in low and middle income countries.

OPEN ACCESS

Citation: Gitaka J, Ogwang C, Ngari M, Akoo P, Olotu A, Kerubo C, et al. (2017) Clinical laboratory reference values amongst children aged 4 weeks to 17 months in Kilifi, Kenya: A cross sectional observational study. PLoS ONE 12(5): e0177382. https://doi.org/10.1371/journal.pone.0177382

Editor: Sanjai Kumar, Food and Drug Administration, UNITED STATES

Received: November 13, 2016
Accepted: April 26, 2017
Published: May 11, 2017

Copyright: © 2017 Gitaka et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The author(s) received no specific funding for this work.

Competing interests: The authors have declared that no competing interests exist.
Introduction

In clinical trials, reference values for clinical laboratory parameters are important for screening for eligibility; diagnosis and grading of toxicities; and management of adverse events. The reference ranges and toxicity grading scales for haematological and biochemical parameters typically used for clinical trials in sub-Saharan Africa are usually derived from industrialized countries or from WHO references that are not region-specific [1–5]. However, typical laboratory parameters in communities may vary based on race, age, gender, diet, local disease patterns and environmental characteristics [6–11].

An upsurge of clinical trials in developing countries in the recent years has led to questions over the use of external references, and the need to determine what is ‘normal’ in local communities in order to be able to interpret eligibility for representative participation in trials and potential adverse events [4, 12–14]. ‘Normal’ may not be ‘optimal’, thus the target population who may ultimately receive an intervention that is being tested may have characteristics that fall outside international reference values when in their usual state of health [15, 16]. Moreover, available reference data may not adequately cover the youngest age groups, be gender-specific, or may have been determined using older instruments or when characteristics of the population and interventions such as bed net distribution or micronutrient supplementation may have been different [17–20].

Reference intervals for biological parameters are usually defined as values falling within two standard deviations (95% prediction) of the mean found in healthy populations [21]. The US-based Clinical Laboratory and Standards Institute (CLSI) guidelines recommend that laboratories establish their reference intervals for their own population, or validate those obtained from a different setting [22, 23].

Adult populations in Africa often have lower haemoglobin, red blood cell counts, haematocrit, mean corpuscular volume, platelets and neutrophils, and higher monocyte and eosinophil counts than Caucasian populations [3, 8, 24]. Creatinine and transaminases are generally comparable to that of Caucasians [16, 23, 24]. Similarly, studies in African children have typically shown that red blood cell parameters such as haemoglobin, haematocrit and mean corpuscular volume are lower than those of Caucasians, with the exception of platelets [25, 26] and eosinophils, which tend to be higher, the latter being attributed to helminth infestation.

The aim of this study was to establish age-specific haematological and biochemistry reference values for typical children aged 4 weeks to 17 months living in Kilifi County in rural Kenya who participated in malaria vaccine trials [27, 28].

Methods

Study site

The study took place in Kilifi district (now part of Kilifi County), Kenya, latitude -3.63, longitude 39.85 degrees [29]. It is a predominantly rural area and the majority of the inhabitants are subsistence farmers from the Mijikenda ethnic group. The staple diet is corn meal, cassava and local green vegetables. The main income generating activities are tourism, small-scale trading, farming, fishing and employment in nearby towns [30]. The climate is tropical with long rains being between April to July and short rains between October and December. There has been a downward trend of malaria prevalence locally and reduction in the densities of the major malaria vectors, with a shift from human to animal feeding [31, 32].
Study participants

We carried out a cross sectional study nested within phase IIb [27] and phase IIIb [28] RTS,S malaria candidate vaccine trials. Further information on trial design and methodology can be found in the primary trial publications [27, 28].

A series of public meetings were held in the study communities and parents who showed interest in the study were invited to bring their children for further examination at the study dispensary. Parents/guardians gave written consent for their children to be enrolled into these trials and only children who were judged to have no serious acute or chronic illness as determined by history and physical examination (defined as not having any signs and symptoms of disease, ambulatory (children older than 1 year) and not underweight, defined as weight-for-age Z score (WAZ) ≥ -2), medical history records or laboratory screening tests were eligible. Other exclusion criteria included a history of allergic reactions, a history of a previous blood transfusion, major congenital defects, or a confirmed or suspected immunodeficiency disorder (e.g. active HIV disease of Stage III or Stage IV severity, as defined by the World Health Organization, at the time of screening). There was no routine testing for HIV in the trials.

Blood samples from eligible children were then obtained before immunisation for haematology (for both trials), and creatinine and alanine transaminase (only for the phase IIb trial). We only used laboratory results taken at baseline (the screening results), prior to the administration of trial interventions which may have otherwise influenced physiological parameters. The only haematology parameter that was consistently done for all participants was haemoglobin. Children with severe anemia, defined as a haemoglobin concentration <5.0g/dL or a haemoglobin concentration <8.0g/dL associated with clinical signs of heart failure or severe respiratory distress were then excluded.

A total of 450 children aged 5–17 months were recruited between March 2007 and August 2007 in the phase IIb trial and a further 904 children were recruited 2009 to 2014 in the phase IIIb trial in two age cohorts: 5–17 months (N = 600), and 6 to 12 weeks (N = 304).

Blood collection

Capillary and venous samples were collected from finger pricks or the antecubital fossa veins respectively. Infants more frequently had capillary sampling due to feasibility. Samples were collected in a 0.5 ml di-potassium ethylene diamine tetra acetic acid (K₂EDTA) tube for haematology and 1ml serum separator tube (SST) tube for biochemistry. Blood samples were transported in cool boxes containing ice packs within four hours of collection to the KEMRI/Wellcome Trust Clinical Trials Laboratory. All samples were collected in the morning hours before midday and processed within 6 hours of collection.

Laboratory analysis

Haematological parameters examined were haemoglobin (Hb), haematocrit (Hct), mean corpuscular haemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelets, white blood count (WBC) and differentials (neutrophils, lymphocytes, monocytes, eosinophils, and basophils) using a Beckman Coulter AcT 5 Diff Haematology Analyzer (Beckman Coulter, USA) [33]. The biochemical parameters were alanine transaminase (ALT) and creatinine (Cr), analysed using a Vitalab Selectra-E clinical chemistry analyser (Vital Scientific (Merck), Netherlands).

Normal and abnormal controls were run daily and no analysis was done if controls were out of range. Assays were done according to manufacturer’s instructions and established standard operating procedures. The KEMRI/Wellcome Trust Clinical Trials Laboratory is a member of two external quality assurance schemes; United Kingdom’s National External Quality
Assessment Service (since 2003) and the Royal College of Pathologist of Australasia–Quality Assurance Program (since 2006); and is also Good Clinical Laboratory Practice (GCLP) accredited by Qualogy Limited since 2006.

Statistical methods

Data were double-entered to an OpenClinica® database from source documents. Data analysis was carried out using Stata 12 (Stata Corp, College Park, TX, USA) and all statistical tests considered significant at \( P < 0.05 \) (two-sided). To obtain the reference ranges we followed the Clinical and Laboratory Standards Institute (CLSI) 2008 guidelines (EP28-A3c) [34]. CLSI recommends a minimum of 120 samples for analysis by nonparametric methods for each partition (e.g. gender, age range).

The sample population was stratified by gender and categorized into the following preconceived age groups: 4 weeks to less than 6 months, 6 months to less than 12 months and 12 months to 17 months. We computed 95% reference ranges, and the 90% confidence limits around each of the upper and lower reference values. Statistical differences by gender were assessed using a Wilcoxon rank-sum test.

For haematology and biochemical variables, we assessed and excluded outlying values in the analysis using Tukey’s method [35], as recommended by CLSI for establishing reference intervals [34, 36] where there are multiple outliers. It comprises calculating the interquartile range (IQR) for each age group, then the lower and upper boundaries were computed as follows: a) lower boundary = 25th percentile–1.5 IQR and b) upper boundary = 75th percentile + 1.5 IQR. Any data points that were outside the lower and upper boundaries were considered outliers and excluded from the ranges.

For comparison with other published reference ranges from Tanzania and European/American children [26, 37], the 90% ranges for lower and upper 95% reference limit were computed for each parameter for ages 1 to 12 months. Tanzania and European/American children 95% lower and upper reference limits were considered not comparable if not within the Kenyan 90% ranges. To compare to our 95% reference ranges, we estimated the means and standard deviation using the number of participants and the 95% reference values, then used one sample t-tests[38]. We could only compare children aged <1 year because this was the age group with available published data.

Ethical considerations

The study protocols of the original vaccine trials were approved by the Kenya Medical Research Institute Ethics Review Committee and regulatory approval was obtained from the Expert Committee on Clinical Trials of the Pharmacy and Poisons Board. The studies were conducted according to the study protocols, Declaration of Helsinki, the International Conference on Harmonization’s Good Clinical Practice standards and the Kenyan regulatory requirements. This secondary analysis was approved by the sponsor, the Malaria Vaccine Initiative (MVI), and the Kenya Medical Research Institute Ethics Review Committee.

Results

There were baseline laboratory results available for a total of 1,294 enrolled subjects: 423 (33%) from the phase IIb trial and 871 (67%) from the phase III trial. Data from 61 (4.7%) participants were excluded because they were outside the target age range. A further 163 (13%) were excluded because they were underweight (WAZ <-2). Among the 1070 participants included in analysis, 450(42%) were female, the median age was 8.2 (IQR 3.2–12.5) months, the median WAZ was -0.54 (IQR -1.18 to 0.12).
For haematology values, results from 1,070 children from both trials were included. Biochemical values were only obtained during the phase IIb RTS,S trial and 381 results were analysed (Fig 1).

The 95% reference ranges and the 90% confidence intervals for the upper and lower limits for the red blood cell indices and platelet counts; white blood cell and chemistry parameters are displayed in Tables 1, 2 and 3 respectively. The 95% reference ranges for creatinine and ALT for 4 weeks to 17 month old children were 26.5 to 45.0 μmol/L and 9.0 to 34.0 IU/L respectively (Table 3).

There were no statistically significant differences by gender for all assessed haematological and biochemical parameters (S1 Table, S2 Table and S3 Table).

Reference haematological values for Tanzanian and European/American infants were examined for comparison (Tables 4 and 5 and S4 Table). We did not find appropriate published reference intervals covering 4 weeks to 17 months of age to compare with our biochemical parameters.

**Discussion**

We have established a set of haematological and biochemistry reference intervals representative of non-underweight children without identified acute or chronic illness aged between 4

---

**Fig 1. Participant flow diagram.**

https://doi.org/10.1371/journal.pone.0177382.g001
weeks to 17 months living in rural Kilifi County. The results describe what is typical in the population, rather than what is optimally healthy.

There was no evidence of gender differences for all haematological and biochemical parameters (see S1, S2 and S3 Tables). This is consistent with previous studies that showed that gender differences for most haematological and chemistry parameters start being evident during adolescence [39–42].

Differences in haematological values among different populations have been attributed to factors such as nutrition, genetic differences, exposure to infectious diseases, environmental factors and socio-economic status. Despite Kenya and Tanzania being neighbouring countries in East Africa, our 2.5th percentile for Hb and Hct; and the 97.5th percentile for WBC, neutrophils, lymphocytes, and basophils were lower than those for Tanzanian children [26]. The 2.5th percentile platelet counts, WBC and monocytes were higher than those for Tanzanian children. The 97.5th percentile platelet counts, monocytes and eosinophils were higher than those for Tanzanian children. Overall, these results suggest that anaemia and inflammation are more common in Kilifi, Kenya than in the Kilimanjaro Region, Tanzania. The 2.5th percentile for neutrophils, lymphocytes, basophils and MCV; and the 97.5th percentile of Hb and Hct were comparable (Table 5 and S4 Table).

Table 1. 95% reference ranges with 90% confidence intervals for selected haematological parameters for Kilifi children aged 1–17 months.

| Parameter/Age group | N* | 95% Reference range | 90% Confidence interval (Lower reference limits) | 90% Confidence interval (Upper reference limits) |
|---------------------|----|---------------------|-----------------------------------------------|-----------------------------------------------|
| **Haemoglobin (g / dl)** |     |                     |                                               |                                               |
| 1 to 6 months       | 358 | 8.1–13.8            | 7.6–8.4                                       | 13.6–14.1                                     |
| 6 to 12 months      | 386 | 7.0–11.5            | 6.9–7.3                                       | 11.4–11.8                                     |
| 12 to 17 months     | 306 | 7.1–11.9            | 6.9–7.5                                       | 11.6–12.1                                     |
| Overall             | 1050| 7.2–12.7            | 7.0–7.5                                       | 12.6–12.9                                     |
| **Haematocrit (%)** |     |                     |                                               |                                               |
| 1 to 6 months       | 299 | 24.8–41.9           | 23.8–25.7                                     | 40.9–43.2                                     |
| 6 to 12 months      | 321 | 23.2–36.1           | 22.6–23.8                                     | 35.1–36.7                                     |
| 12 to 17 months     | 222 | 25.0–36.6           | 23.4–25.6                                     | 35.7–37.1                                     |
| Overall             | 842 | 23.9–38.3           | 23.3–24.7                                     | 37.8–38.7                                     |
| **MCHC (g/dL)**     |     |                     |                                               |                                               |
| 1 to 6 months       | 301 | 31.2–34.7           | 30.9–31.4                                     | 34.5–35.1                                     |
| 6 to 12 months      | 322 | 29.5–33.8           | 29.2–29.9                                     | 33.7–34.1                                     |
| 12 to 17 months     | 224 | 28.9–33.5           | 28.2–29.0                                     | 33.5–34.2                                     |
| Overall             | 847 | 29.4–34.4           | 29.2–29.6                                     | 34.2–34.5                                     |
| **MCV (fl)**        |     |                     |                                               |                                               |
| 1 to 6 months       | 305 | 57–100              | 55–59                                         | 98–103                                        |
| 6 to 12 months      | 328 | 51–78               | 50–53                                         | 77–80                                         |
| 12 to 17 months     | 227 | 50–79               | 48–51                                         | 77–81                                         |
| Overall             | 860 | 52–97               | 51–53                                         | 96–98                                         |
| **Platelets (×10³ cells/μL)** | |                     |                                               |                                               |
| 1 to 6 months       | 303 | 74–765              | 23–113                                        | 713–835                                       |
| 6 to 12 months      | 318 | 104–798             | 84–151                                        | 756–837                                       |
| 12 to 17 months     | 217 | 184–769             | 142–220                                       | 747–807                                       |
| Overall             | 838 | 84–773              | 55–100                                        | 752–812                                       |

N* varies for each age group as some lab tests were not done for all participants and the following outliers were excluded from analysis: Hb-19, Hct-5, MCHC-8, MCV-0, Platelets- 15.

https://doi.org/10.1371/journal.pone.0177382.t001
Table 2. 95% reference ranges with 90% confidence intervals for selected white blood cells parameters for Kilifi children aged 1–17 months.

| Parameter/Age group | N* | 95% reference values | 90% confidence interval (Lower reference Limits) | 90% confidence interval (Upper reference Limits) |
|---------------------|----|----------------------|-----------------------------------------------|-----------------------------------------------|
| WBC (×10³ cells/μL) | 293 | 4.74–14.77           | 4.50–5.41                                    | 13.75–15.87                                  |
| 1 to 6 months       | 321 | 6.70–17.39           | 6.20–7.04                                    | 16.70–17.91                                  |
| 6 to 12 months      | 218 | 5.84–16.66           | 5.05–6.50                                    | 16.10–17.75                                  |
| Overall             | 832 | 5.71–16.72           | 5.31–6.05                                    | 16.41–17.08                                  |
| Neutrophils (×10³ cells/μL) | 211 | 0.57–3.53           | 0.37–0.68                                    | 3.32–3.77                                    |
| 1 to 6 months       | 234 | 1.05–4.25            | 0.71–1.12                                    | 3.93–4.39                                    |
| 6 to 12 months      | 137 | 0.95–5.56            | 0.76–1.02                                    | 4.89–5.97                                    |
| Overall             | 582 | 0.70–4.39            | 0.64–0.82                                    | 4.18–4.45                                    |
| Lymphocytes (×10³ cells/μL) | 229 | 3.06–9.04          | 2.14–3.45                                    | 8.52–9.47                                    |
| 1 to 6 months       | 237 | 3.38–10.97           | 3.06–3.71                                    | 10.83–11.35                                  |
| 6 to 12 months      | 137 | 2.97–9.75            | 2.19–3.21                                    | 9.38–10.37                                   |
| Overall             | 603 | 3.13–10.20           | 2.99–3.39                                    | 9.87–10.77                                   |
| Monocytes (×10³ cells/μL) | 218 | 0.38–1.89         | 0.28–0.44                                    | 1.81–1.98                                    |
| 1 to 6 months       | 234 | 0.60–2.06            | 0.51–0.65                                    | 1.96–2.17                                    |
| 6 to 12 months      | 134 | 0.48–1.91            | 0.31–0.55                                    | 1.72–1.94                                    |
| Overall             | 586 | 0.48–1.93            | 0.43–0.52                                    | 1.91–2.01                                    |
| Eosinophils (×10³ cells/μL) | 211 | 0.07–0.70         | 0.05–0.11                                    | 0.61–0.78                                    |
| 1 to 6 months       | 232 | 0.07–1.20            | 0.04–0.09                                    | 1.11–1.31                                    |
| 6 to 12 months      | 134 | 0.05–1.20            | 0.03–0.08                                    | 0.99–1.28                                    |
| Overall             | 577 | 0.06–0.98            | 0.05–0.08                                    | 0.92–1.02                                    |
| Basophils (×10³ cells/μL) | 193 | 0.01–0.06         | 0.00–0.01                                    | 0.05–0.07                                    |
| 1 to 6 months       | 214 | 0.01–0.04            | 0.00–0.01                                    | 0.04–0.04                                   |
| 6 to 12 months      | 123 | 0.01–0.06            | 0.00–0.01                                    | 0.04–0.06                                   |
| Overall             | 583 | 0.01–0.06            | 0.00–0.01                                    | 0.05–0.06                                   |

N* varies for each age group as some lab tests were not done for all participants and the following outliers were excluded from analysis: (WBC– 29, Neutrophils- 31, Lymphocytes- 21, Monocytes- 27, Eosinophils- 36, Basophils- 30).

https://doi.org/10.1371/journal.pone.0177382.t002

Table 3. 95% reference ranges with 90% confidence intervals for selected biochemistry parameters for Kilifi children aged 1–17 months.

| Parameter       | N* | 95% Reference values | 90% Confidence interval (Lower reference Limits) | 90% Confidence interval (Upper reference Limits) |
|-----------------|----|----------------------|-----------------------------------------------|-----------------------------------------------|
| Creatinine (μmol/L) | 419 | 27–45               | 25–28                                         | 44–46                                         |
| ALT (IU/L)      | 408 | 9–34                | 7–10                                          | 32–35                                         |

N* varies for each parameter because the following outliers were excluded from analysis: ALT- 14, Cr-3.

https://doi.org/10.1371/journal.pone.0177382.t003
Several African studies that have shown lower red blood cell indices in children and adults [16, 24, 25, 43] compared to American or European children [37]; we also observed this for Hb, Hct and MCV (Table 5 and S4 Table). This may be attributed to several factors that are common in the community, including malaria, other parasitic infestations [44, 45], haemoglobinopathies [46] and iron deficiency anaemia [47].

The 2.5th and 97.5th percentile platelet counts in children from Kilifi indicated values that would be classified as thrombocytopenia and thrombocytosis respectively if evaluated by reference ranges among European/American populations. However, they were not associated with clinical features. This was also observed amongst Tanzanian children (Table 5 and S4 Table). Thrombocytopenia can result from impaired platelet production, increased platelet destruction (immune and non–immune) and abnormal vascular distribution e.g. splenic sequestration. One potential cause of thrombocytopenia in African populations is P. falciparum malaria [48, 49].

Thrombocytosis may be attributed to persistent elevated thrombopoetin levels observed in iron deficiency [50] or inflammation that stimulates its production in the liver [51].

### Table 4. 95% reference intervals for selected haematological parameters: Kenyan infants aged 1 to less than 12 months (current study), compared to published data from Tanzania and United States/Europe.

| Parameter       | Kenya (current study) | *Tanzania (2010) | *US/Europe (2006) |
|-----------------|-----------------------|------------------|-------------------|
|                 | Lower 95% reference value | 90% Confidence interval for lower reference value | Upper 95% reference value | 90% Confidence interval for upper reference value | 95% Reference ranges | 95% Reference ranges |
| Haemoglobin (g/dl) | 7.3 | 7.0–7.6 | 13.2 | 12.9–13.5 | 8.1–13.2 | 9.4–13.0 |
| Haematocrit (%)   | 23.5 | 22.9–24.3 | 39.2 | 38.6–39.9 | 25.1–38.6 | 28–42 |
| MCV (fl)          | 53.4 | 52.2–55.0 | 98.6 | 97.0–99.3 | 53.3–96.6 | 70–98 |
| Platelets (10^3/μL) | 72.7 | 51.5–89.6 | 769.2 | 738.4–822.8 | 25–708 | 150–400 |

*References: Tanzanian data (Buchanan et al. 2010) and USA/European data (Simpkin & Hinchliffe 2006).

https://doi.org/10.1371/journal.pone.0177382.t004

### Table 5. 95% reference intervals for white blood cell counts for Kenyan infants aged 1 to less than 12 months, compared to published data from Tanzania and United States/Europe.

| Parameter                  | Kenya (current study) | *Tanzania (2010) | *US/Europe (2006) |
|----------------------------|-----------------------|------------------|-------------------|
| WBC (x10^3 cells/μL)       | 5.6 | 5.2–5.9 | 16.6 | 16.2–16.9 | 2.0–17.3 | 5.0–17.0 |
| Neutrophils (x10^3 cells/μL) | 0.7 | 0.6–0.8 | 4.1 | 3.9–4.2 | 0.7–4.6 | 0.7–8.0 |
| Lymphocytes (x10^3 cells/μL) | 3.3 | 2.9–3.5 | 10.2 | 9.9–10.8 | 3.3–11.8 | 3.3–11.5 |
| Monocytes (x10^3 cells/μL)  | 0.5 | 0.42–0.53 | 2.0 | 1.9–10.8 | 0.2–1.5 | 0.2–1.3 |
| Eosinophils (x10^3 cells/μL) | 0.06 | 0.05–0.08 | 0.9 | 0.8–1.0 | 0.1–0.8 | 0.05–1.1 |
| Basophils (x10^3 cells/μL)  | 0.01 | 0.01–0.01 | 0.07 | 0.06–0.08 | 0.01–0.14 | 0.02–0.13 |

*References: Tanzanian data (Buchanan et al. 2010) and USA/European data (Simpkin & Hinchliffe 2006).

https://doi.org/10.1371/journal.pone.0177382.t005
inflammation is commonly the result of environmental enteric dysfunction, associated with poor sanitation resulting in gut infections, malabsorption and malnutrition [52, 53]. These findings accord with recent studies indicating that platelet counts may be higher in African paediatric populations compared to Caucasian populations [26, 43, 54, 55].

The WBC 2.5th and 97.5th percentiles were higher and lower respectively than those for Tanzanian and American/European populations. Other African studies have shown that the WBC counts in infants tend to be similar or lower than those of Caucasians [26, 43]. The 2.5th percentile for eosinophils was comparable to that of American/European populations while the 97.5th percentile was comparable with those for Tanzania (Table 5 and S4 Table).

The 97.5th percentile for neutrophils was higher in the European/American infants compared to our study (Table 5 and S4 Table), as other African studies have demonstrated [26, 43, 56]. This may due to sub-clinical infection. This has also been attributed to a regulatory variant in the Duffy antigen receptor for chemokines [56].

Eosinophils had a lower upper limit in Kilifi when compared to European/American infants, but higher than those for Tanzanian children (Table 5 and S4 Table). Some studies have shown that eosinophils tend to be elevated in African populations due to environmental factors such as helminthiasis [43].

The monocyte 95% intervals were comparable for both Tanzanian and European/American populations, while Kilifi had a higher lower and upper limit (Table 5 and S4 Table). Monocytes have been shown to play an important role in immune mechanisms against protozoal infections such as malaria, with elevated monocytes levels being observed in malaria endemic settings [57–59]. The study area is malaria endemic and this might have contributed to higher monocyte count compared to Tanzanian and European/American infants.

Strengths and limitations

The major strength of the study is that we analysed a large sample (>1000) of children in a community setting at the time of recruitment for a clinical trial. We believe our reference ranges are representative of typical community children in similar settings in Africa who would ultimately benefit from successful trials. Our study had a number of limitations. Screening could not conclusively rule out all forms of illness such as parasitic infestations, sickle cell anaemia, thalassaemia and micronutrient deficiencies that may have affected the parameters. The HIV status of the children was also not assessed, but in apparently healthy children HIV prevalence would be expected to be less than 1%. The reference ranges are therefore representative of children in the community without acute illness who would typically be eligible for clinical trials, rather than intended to define a state of optimal health. There was no suitable study to compare our biochemistry results with. Because of sample size, biochemistry results were not partitioned by age groups.

Conclusion

This study, like others in Africa, has shown that commonly used European/American reference ranges do not well suit typical African populations. This reaffirms the need for locally-derived reference values for clinical research in order to appropriately assign eligibility and interpret adverse events.

Supporting information

S1 Table. 95% reference ranges with 90% confidence intervals for selected haematological parameters for Kilifi children aged 1–17 months stratified by gender. (PDF)
S2 Table. 95% reference ranges with 90% confidence intervals for selected white blood cells parameters for Kilifi Children aged 1–17 months stratified by gender. (PDF)

S3 Table. 95% reference ranges with 90% confidence intervals for selected biochemistry parameters for Kilifi Children aged 1–17 months stratified by gender. (PDF)

S4 Table. Selected haematological parameters for Kenyan infants aged 1 to less than 12 months, compared to published data from Tanzania and United States/Europe. (PDF)

Acknowledgments

We would like to thank the study participants who took part in the two RTS,S trials. PATH—Malaria Vaccine Initiative (MVI) gave us permission to use their data. Permission to submit the manuscript for publication was given by the Director, Kenya Medical Research Institute.

Author Contributions

Conceptualization: JG PA PN RC JAB.

Data curation: CO CK MN GF GN TO GM KA BL.

Formal analysis: JG CO MN GF JAB.

Funding acquisition: PN AO RC.

Investigation: JG CO CK PA PN AO GN TO GM KA BL.

Methodology: JG CO MN PN RC JAB.

Project administration: JG CO MN PN RC.

Resources: PN RC BL.

Software: MN GF.

Supervision: RC JAB.

Validation: MN GF JAB.

Visualization: JG CO MN PN RC JAB.

Writing – original draft: JG CO.

Writing – review & editing: JG CO MN CK PA PN GN TO GM KA BL RC JAB.

References

1. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. July 12, 2014. Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf.

2. Syndrome DoAI. The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. 2004. Available from: http://www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf.

3. Clement E. Zeh COOaLAM. Laboratory Reference Intervals in Africa. September 21, 2012 [cited 16th July, 2014]. In: Blood Cell—An Overview of Studies in Hematology [Internet]. InTech, [cited 16th July, 2014]; [18].
4. Lusingu J, Olotu A, Leach A, Lievens M, Vekemans J, Olivier A, et al. Safety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. PLoS One. 2010; 5(11): e14090. Epub 2010/12/03. PubMed Central PMCID: PMC2993932. https://doi.org/10.1371/journal.pone.0014090 PMID: 21124768

5. WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity.: Vitamin and Mineral Nutrition Information System. Geneva, World Health Organization, 2011.; 2011. Available from: http://www.who.int/vmnis/indicators/haemoglobin.

6. Vincent-Viry M, Fournier B, Gueguen R, Henny J, Monneau JP, Siest G. Biochemical values of immigrant groups in north-east France. Ann Hum Biol. 1990; 17(4):277–87. Epub 1990/07/01. PMID: 2393252

7. Tsegaye A, Messele T, Tilahun T, Hailu E, Sahlu T, Doorly R, et al. Immunohematological reference ranges for adult Ethiopians. Clin Diagn Lab Immunol. 1999; 6(3):410–4. Epub 1999/05/04. PubMed Central PMCID: PMC103732. PMID: 10225845

8. Tugume SB, Piwowar EM, Lutalo T, Mugyenyi PN, Grant RM, Mangeni FW, et al. Hematological reference ranges among healthy Ugandans. Clin Diagn Lab Immunol. 1995; 2(2):233–5. Epub 1995/03/01. https://doi.org/10.1371/journal.pmed.1001228 PMID: 11256567

9. Maiga D, Akanmor BD, Chocarro L. Regulatory oversight of clinical trials in Africa: progress over the past 5 years. Vaccine. 2009; 27(52):7249–52. Epub 2009/09/15. https://doi.org/10.1016/j.vaccine.2009.08.113 PMID: 19748580

10. Lang T, Siribaddana S. Clinical trials have gone global: is this a good thing? PLoS Med. 2012; 9(6): e1001228. Epub 2012/06/22. PubMed Central PMCID: PMC3373653. https://doi.org/10.1371/journal.pmed.1001228 PMID: 22719226

11. Schnabl K, Chan MK, Gong Y, Adeli K. Closing the gaps in paediatric reference intervals: the CALIPER initiative. The Clinical biochemist Reviews / Australian Association of Clinical Biochemists. 2008; 29(3):89–96. Epub 2008/12/25. PubMed Central PMCID: PMC2605413.

12. Allen LH. Interventions for micronutrient deficiency control in developing countries: past, present and future. J Nutr. 2003; 133(11 Suppl 2):387S–8S.

13. Bhatt S, Weiss DJ, Cameron E, Bisanzio D, Mappin B, Dalrymple U, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature. 2015; 526(7572):207–11. PubMed Central PMCID: PMC4820050. https://doi.org/10.1038/nature15535 PMID: 26375008

14. Ceriotti F, Hinzmann R, Panteghini M. Reference intervals: the way forward. Annals of clinical biochemistry. 2009; 46( Pt 1):8–17. https://doi.org/10.1258/acb.2008.008170 PMID: 19103955

15. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline.2008 Wayne, PA: Clinical and Laboratory Standards Institute.October 27, 2013; 28.
23. Zeh C, Amornkul PN, Inzaule S, Ondoa P, Oyar B, Mwaengo DM, et al. Population-based biochemical, immunologic and hematological reference values for adolescents and young adults in a rural population in Western Kenya. PLoS One. 2011; 6(6):e21040. Epub 2011/06/30. PubMed Central PMCID: PMC3119664. https://doi.org/10.1371/journal.pone.0021040 PMID: 21713038

24. Kibaya RS, Bautista CT, Sawe FK, Shaffer DN, Sateren WB, Scott PT, et al. Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya. PLoS One. 2008; 3(10):e3327. Epub 2008/10/04. PubMed Central PMCID: PMC2553265. https://doi.org/10.1371/journal.pone.0003327 PMID: 18833329

25. Odutola AA, Afolabi MO, Jafali J, Baldeh I, Owolabi OA, Owiafe P, et al. Haematological and biochemical reference values of Gambian infants. Tropical medicine & international health: TM & IH. 2014; 19 (3):275–83.

26. Buchanan AM, Muro FJ, Gratz J, Crump JA, Musyoka AM, Sichanghi MW, et al. Establishment of haematological and immunological reference values for healthy Tanzanian children in Kilimanjaro Region. Tropical medicine & international health: TM & IH. 2010; 15(9):1011–21. Epub 2010/07/20. PubMed Central PMCID: PMC3024440.

27. Olotu A, Lusingu J, Leach A, Lieve M, Vekemans J, Msham S, et al. Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial. The Lancet infectious diseases. 2011; 11(2):102–9. Epub 2011/01/18. PubMed Central PMCID: PMC3341451. https://doi.org/10.1016/S1473-3099(10)70262-0 PMID: 21237715

28. Rts SCTP Agnandji ST, Lell B, Fernandes JF, Abossolo BP Methogo BG, et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. The New England journal of medicine. 2012; 367(24):2284–95. Epub 2012/11/10. https://doi.org/10.1056/NEJMoa1208394 PMID: 2316909

29. Spraggs C, McCarthy A, McCarthy L, Hong G, Hughes A, Lin X, et al. Genetic variants in the epithelial sodium channel associate with oedema in type 2 diabetic patients receiving the peroxisome proliferator-activated receptor gamma agonist fargliflozin. Pharmacogenet Genomics. 2007; 17(12):1065–76. https://doi.org/10.1097/FPC.0b013e3282f1b2d7 PMID: 18004211

30. Marsh VM, Kamuya DM, Mlamba AM, Williams TN, Molynieux SS. Experiences with community engagement and informed consent in a genetic cohort study of severe childhood diseases in Kenya. BMC medical ethics. 2010; 11:13. Epub 2010/07/17. PubMed Central PMCID: PMC2918624. https://doi.org/10.1186/1472-6939-11-13 PMID: 20633282

31. Mwangangi JM, Mbogo CM, Orindi BO, Muturi EJ, Midega JT, Nzovu J, et al. Shifts in malaria vector species composition and transmission dynamics along the Kenyan coast over the past 20 years. Malaria journal. 2013; 12:13. PubMed Central PMCID: PMC3544599. https://doi.org/10.1186/1475-2875-12-13 PMID: 23297732

32. Okiro EA, Hay SI, Gikandi PW, Sharif SK, Noor AM, Peshu N, et al. The decline in paediatric malaria admissions on the coast of Kenya. Malaria journal. 2007; 6:151. PubMed Central PMCID: PMC2194691. https://doi.org/10.1186/1475-2875-6-151 PMID: 18005422

33. Pickett JA, Birkett MA, Bruce TJ, Chamberlain K, Gordon-Weeks R, Matthes MC, et al. Developments in aspects of ecological phytochemistry: the role of cis-jasmone in inducible defence systems in plants. Phytochemistry. 2007; 68(22–24):2937–45. https://doi.org/10.1016/j.phytochem.2007.09.025 PMID: 18023830

34. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline—Third Edition. CLSI document EP28-A3c. Wayne, PA: Clinical and Laboratory Standards Institute; 2008

35. Tukey JW. Exploratory Data Analysis. Reading, MA: Addison-Wesley; 1977:688.

36. Dixon WJ. Processing Data for Outliers. Biometrics. 1953; 9:74–89.

37. Simpkin P & Hinchliffe RF (2006) Reference values. In: Pediatric Hematology, 3rd edn. (eds Arceci R, Hann IM & Smith OP) Blackwell Publishing Ltd, Oxford, UK, pp. 792–810.

38. Cochrane Handbook for Systematic Reviews of Interventions. Available from: http://handbook.cochrane.org/chapter_7/7_7_3_2_obtaining_standard_deviations_from_standard_errors_and.htm.

39. Gomez P, Coca C, Vargas C, Acebillo J, Martinez A. Normal reference-intervals for 20 biochemical variables in healthy infants, children, and adolescents. Clin Chem. 1984; 30(3):407–12. Epub 1984/03/01. PMID: 6697487

40. Burritt MF, Stockbower JM, Forsman RW, Offord KP, Bergstralh EJ, Smithson WA. Pediatric reference intervals for 19 biologic variables in healthy children. Mayo Clinic proceedings. 1990; 65(3):329–36. Epub 1990/03/01. PMID: 2314122

41. Yip R, Johnson C, Dallman PR. Age-related changes in laboratory values used in the diagnosis of anemia and iron deficiency. The American journal of clinical nutrition. 1984; 39(3):427–36. Epub 1984/03/01. PMID: 6695842
42. Castro OL, Haddy TB, Rana SR. Age- and sex-related blood cell values in healthy black Americans. Public health reports. 1987; 102(2):232–7. Epub 1987/03/01. PubMed Central PMCID: PMC1477821. PMID: 3104982

43. Lugada ES, Mermin J, Kaharuza F, Ulvestad E, Were W, Langeland N, et al. Population-based hematologic and immunologic reference values for a healthy Ugandan population. Clin Diagn Lab Immunol. 2004; 11(1):29–34. Epub 2004/01/13. PubMed Central PMCID: PMC321349. https://doi.org/10.1128/CDLI.11.1.29-34.2004 PMID: 14715541

44. Ashford RW, Craig PS, Oppenheimer SJ. Polyparasitism on the Kenya coast. 1. Prevalence, and association between parasitic infections. Annals of tropical medicine and parasitology. 1992; 86(6):671–9. Epub 1992/12/01. PMID: 1304710

45. Brooker S, Peshu N, Warn PA, Mosobo M, Guyatt HL, Marsh K, et al. The epidemiology of hookworm infection and its contribution to anaemia among pre-school children on the Kenyan coast. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1999; 93(3):240–6. Epub 1999/09/24. PMID: 10492749

46. Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harbor perspectives in medicine. 2012; 2(9):a011692. Epub 2012/09/07. https://doi.org/10.1101/cshperspect.a011692 PMID: 22951448

47. Atkinson SH, Armitage AE, Khandwala S, Mwangi TW, Uyoga S, Bejon PA, et al. Combinatorial effects of malaria season, iron deficiency, and inflammation determine plasma hepcidin concentration in African children. Blood. 2014; 123(21):3221–9. PubMed Central PMCID: PMC4046425. https://doi.org/10.1182/blood-2013-10-533000 PMID: 24596418

48. Pukrittayakamee S, White NJ, Clements R, Chittammas S, Karges HE, Desakorn V, et al. Activation of the coagulation cascade in falciparum malaria. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1989; 83(6):762–6. PMID: 2482560

49. Gerardin P, Rogier C, Ka AS, Jouvenel P, Brousse V, Imbert P. Prognostic value of thrombocytopenia in African children with falciparum malaria. The American journal of tropical medicine and hygiene. 2002; 66(6):686–91. PMID: 12224575

50. Schafer AI. Thrombocytosis. The New England journal of medicine. 2004; 350(12):1211–9. https://doi.org/10.1056/NEJMra035363 PMID: 15028825

51. Wolber EM, Fandrey J, Frackowiak U, Jelkmann W. Hepatic thrombopoietin mRNA is increased in acute inflammation. Thrombosis and haemostasis. 2001; 86(6):1421–4. PMID: 11776309

52. Crane RJ, Jones KD, Berkley JA. Environmental enteric dysfunction: an overview. Food Nutr Bull. 2015; 36(Suppl):S76–87. PubMed Central PMCID: PMCPMC4472379. https://doi.org/10.1177/15648265150361S113 PMID: 25902619

53. Campbell DI, Murch SH, Elia M, Sullivan PB, Sanyang MS, Jobarteh B, et al. Chronic T cell-mediated enteropathy in rural west African children: relationship with nutritional status and small bowel function. Pediatr Res. 2003; 54(3):306–11. https://doi.org/10.1203/01.PDR.0000076666.16021.5E PMID: 12788978

54. Humberg A, Kammer J, Mordmuller B, Kremsner PG, Leil B. Haematological and biochemical reference intervals for infants and children in Gabon. Tropical medicine & international health: TM & IH. 2011; 16(3):343–8. Epub 2011/01/05.

55. Kumwenda NI, Khonje T, Mipando L, Nkanaunena K, Katundu P, Lubega I, et al. Distribution of haematological and chemical pathology values among infants in Malawi and Uganda. Paediatrics and international child health. 2012; 32(4):213–27. Epub 2012/11/21. PubMed Central PMCID: PMCPMC3571100. https://doi.org/10.1179/0261959612Y.0000000034 PMID: 23164296

56. Reich D, Nalls MA, Kao WH, Akylbekova EL, Tandon A, Patterson N, et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS genetics. 2009; 5(1):e1000360. Epub 2009/01/31. PubMed Central PMCID: PMC2628742. https://doi.org/10.1371/journal.pgen.1000360 PMID: 19180233

57. LuneI F, Druilhe P. Effector cells involved in nonspecific and antibody-dependent mechanisms directed against Plasmodium falciparum blood stages in vitro. Infection and immunity. 1989; 57(7):2043–9. PubMed Central PMCID: PMCPMC313839. PMID: 2659533

58. Tebo AE, Kremsner PG, Luty AJ. Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Experimental parasitology. 2001; 98(1):20–8. https://doi.org/10.1006/expv.2001.4619 PMID: 11426948

59. Manson's Tropical Diseases. 22nd ed. UK: Saunders Ltd; 2009. 1800 p.